Generation of a soluble and stable apoptin-EGF fusion protein, a targeted viral protein applicable for tumor therapy

Niesler, Nicole; Arndt, Janine; Silberreis, Kim; Fuchs, Hendrik

doi:10.1016/j.pep.2020.105687

Cited by 4 publications

(3 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All these might be attributed to the fact that apatinib, as an oral small molecule TKI against angiogenesis, can block VEGFR-2 in advanced GCA patients and reduce the activation of mitogen-activated protein kinase, thus inhibiting the proliferation of vascular endothelial cells. Preliminary studies reported a promising result of apatinib treatment for patients with advanced rectal cancer, advanced non-small-cell lung cancer, and advanced cervical cancer, in which their serum CEA levels decreased significantly, the survival time prolonged, with good safety profile [ 18 – 21 ]. Nevertheless, there is no consensus about a first-line chemotherapy regimen for patients with advanced gastric cancer, and this study thus was designed to intend to specifically determine an effective therapy.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma

Gao

Shi

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Objective. To evaluate the efficacy of low dose apatinib plus chemotherapy on advanced gastric carcinoma. Methods. Eligible 50 patients with advanced gastric carcinoma admitted to the hospital from January 2019 to March 2020 were enrolled, and they were assigned into the control group ( n = 25 , chemotherapy) and observation group (apatinib plus chemotherapy). Changes of CEA, CA72-4, and VEGF levels were measured, and the efficacy of the two groups was evaluated by referring to KPS and RECIST. Results. Significant reduction was observed in CEA, CA72-4, and VEGF in both groups, and the treatment in the observation group resulted in a greater reduction (all P < 0.05 ). The observation group obtained significantly higher KPS scores of compared with the control group ( P < 0.05 ). In addition, the treatment in the observation group led to a better control rate in relative to the control group according to RECIST the score ( P < 0.05 ). Conclusion. The combination of low dose apatinib and chemotherapy might be a promising option for advanced gastric cancer and it merits clinical application.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma

Gao

Shi

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…To examine, whether HCT 116 and MDA-MB-453 cells express EGFR, cells were lysed and analysed as described in previous work [ 41 ]. Western blot was conducted with a rabbit monoclonal EGFR-antibody (Abcam, Cambridge, United Kingdom) and a mouse monoclonal β-Actin-antibody (Merck KGaA, Darmstadt, Germany) as loading control (see also Additional file 11 ).…”

Section: Methodsmentioning

confidence: 99%

“…Additional MTT assays were performed with the mouse fibroblast cell lines NIH3T3 and HER14 (NIH3T3 cells stably transfected with human EGFR) [ 41 ]. The cells were cultured in DMEM supplemented with 10% fetal bovine serum, 100 U/mL penicillin as well as 100 μg/mL streptomycin and were grown at 37 °C and 5% CO 2 .…”

Section: Methodsmentioning

confidence: 99%

A cleavable peptide adapter augments the activity of targeted toxins in combination with the glycosidic endosomal escape enhancer SO1861

Schulze,

Asadian-Birjand,

Pradela

et al. 2024

BMC Biotechnol

Self Cite

View full text Add to dashboard Cite

Background Treatment with tumor-targeted toxins attempts to overcome the disadvantages of conventional cancer therapies by directing a drug’s cytotoxic effect specifically towards cancer cells. However, success with targeted toxins has been hampered as the constructs commonly remain bound to the outside of the cell or, after receptor-mediated endocytosis, are either transported back to the cell surface or undergo degradation in lysosomes. Hence, solutions to ensure endosomal escape are an urgent need in treatment with targeted toxins. In this work, a molecular adapter that consists of a cell penetrating peptide and two cleavable peptides was inserted into a targeted toxin between the ribosome-inactivating protein dianthin and the epidermal growth factor. Applying cell viability assays, this study examined whether the addition of the adapter further augments the endosomal escape enhancement of the glycosylated triterpenoid SO1861, which has shown up to more than 1000-fold enhancement in the past. Results Introducing the peptide adapter into the targeted toxin led to an about 12-fold enhancement in the cytotoxicity on target cells while SO1861 caused a 430-fold increase. However, the combination of adapter and glycosylated triterpenoid resulted in a more than 4300-fold enhancement and in addition to a 51-fold gain in specificity. Conclusions Our results demonstrated that the cleavable peptide augments the endosomal escape mediated by glycosylated triterpenoids while maintaining specificity. Thus, the adapter is a promising addition to glycosylated triterpenoids to further increase the efficacy and therapeutic window of targeted toxins.

show abstract

Self-assembled small messenger RNA nanospheres for efficient therapeutic apoptin expression and synergistic Gene-Chemotherapy of breast cancer

Tang

Liao

Wang

et al. 2021

Journal of Colloid and Interface Science

View full text Add to dashboard Cite

Generation of a soluble and stable apoptin-EGF fusion protein, a targeted viral protein applicable for tumor therapy

Cited by 4 publications

References 59 publications

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma

A cleavable peptide adapter augments the activity of targeted toxins in combination with the glycosidic endosomal escape enhancer SO1861

Self-assembled small messenger RNA nanospheres for efficient therapeutic apoptin expression and synergistic Gene-Chemotherapy of breast cancer

Contact Info

Product

Resources

About